

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

SYNTHESIS OF NOVEL 1,2,4-TRIAZOLOQUINAZOLINE RING SYSTEMS

József Reiter^a; László Pongó^a

^a EGIS Pharmaceuticals, Budapest, HUNGARY

To cite this Article Reiter, József and Pongó, László(1989) 'SYNTHESIS OF NOVEL 1,2,4-TRIAZOLOQUINAZOLINE RING SYSTEMS', *Organic Preparations and Procedures International*, 21: 2, 163 – 171

To link to this Article: DOI: 10.1080/00304948909356362

URL: <http://dx.doi.org/10.1080/00304948909356362>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>


This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF NOVEL 1,2,4-TRIAZOLOQUINAZOLINE RING SYSTEMS †


József REITER* and László PONGO
EGIS Pharmaceuticals, P. O. Box 100, H-1475 Budapest, HUNGARY

The reaction of β -ketoesters (1) with 5-amino-3-Q-1H-1,2,4-triazoles (2) may lead to four type of condensed ring derivatives 3-6 (Scheme 1). These compounds can exist in different tautomeric forms arising from the triazolo-pyrimidinone skeleton. The structure of 3 ($R^1 = \text{CH}_3$, $R^2 = \text{H}$) and 4 ($R^1 = \text{CH}_3$, $R^2 = \text{H}$) type products obtained from alkyl acetoacetates (1, $R^1 = \text{CH}_3$, $R^2 = \text{H}$) and different triazoles 2 was established in a previous paper of this series¹ with the help of their UV and ¹³C-NMR spectra. It was stated¹ that the UV spectra of these derivatives 3 and 4 ($R^1 = \text{CH}_3$, $R^2 = \text{H}$) in ethanol or methanol were characterised by two absorption bands appearing at about 230 and 270 nm and at 208 and 290 nm, respectively; they differed significantly from those of the corresponding spectra of derivatives 5 and 6 ($R^1 = \text{CH}_3$, $R^2 = \text{H}$) characterised by three and one absorption bands, respectively.



It was also stated¹ that in the ¹³C-NMR spectra of the [1,5-a] type derivatives **3** and **4** ($R^1 = \text{CH}_3$, $R^2 = \text{H}$) taken in DMSO-d₆ solution, the triazolo carbon atom 2 appeared at about 163 ppm while that of the analogous triazolo carbon atom 3 of the [4,3-a] type derivatives **5** and **6** ($R^1 = \text{CH}_3$, $R^2 = \text{H}$) is at about 143 ppm, thus offering a possibility of an easy differentiation between them. The differentiation between the "ring acylated" derivatives **3** and **5** ($R^1 = \text{CH}_3$, $R^2 = \text{H}$) and those of the isomeric "acylamino" derivatives **4** and **6** ($R^1 = \text{CH}_3$, $R^2 = \text{H}$) was made possible by the chemical shifts of the carbonyl carbon atoms that appeared at about 154 and 160 ppm, respectively.¹ These guidelines were used in the structure elucidation of the products of type **3** and **4** obtained from ethyl 2-oxocyclopentanecarboxylate [**1**, $R = \text{C}_2\text{H}_5$, $R^1 + R^2 = (\text{CH}_2)_3$] and their tetrahydrothiophene analogues [**1**, $R = \text{CH}_3$, $R^1 + R^2 = \text{CH}_2\text{SCH}_2$ and $\text{CH}_2\text{CH}_2\text{S}$, respectively] with derivatives **2**.² However, there remained considerable confusion regarding the structure of the products obtained from other homocyclic β-ketoesters, e. g. from the reaction of ethyl 2-oxocyclohexanecarboxylate [**1**, $R = \text{C}_2\text{H}_5$, $R^1 + R^2 = (\text{CH}_2)_4$] and derivatives **2**. Thus structure **3a** [$\text{Q} = \text{H}$, $R^1 + R^2 = (\text{CH}_2)_4$] initially proposed without evidence³ for the product obtained from the reaction of **1** [$R = \text{C}_2\text{H}_5$, $R^1 + R^2 = (\text{CH}_2)_4$] and 5-amino-1*H*-1,2,4-triazole (**2**, $\text{Q} = \text{H}$) was later modified to structures **4a** or **6a** [$\text{Q} = \text{H}$, $R^1 + R^2 = (\text{CH}_2)_4$] on the basis of an analogy with tetrazoles,⁴ later structure **3a** [$\text{Q} = \text{H}$, $R^1 + R^2 = (\text{CH}_2)_4$] was resurrected⁵ without evidence, and finally structure **3a** [$\text{Q} = \text{H}$, $R^1 + R^2 = (\text{CH}_2)_4$] was assigned on the basis of ¹H-NMR.⁶

As a continuation of our studies in the 1,2,4-triazole series, ethyl 2-oxocyclohexanecarboxylate [**1**, $R = \text{C}_2\text{H}_5$, $R^1 + R^2 = (\text{CH}_2)_4$] was reacted with 5-amino-3-methylthio- and 3-morpholino-1*H*-1,2,4-triazoles [**2**, $\text{Q} = \text{methylthio}$ and morpholino , respectively] in acetic acid to yield the corresponding 2-methylthio- and 2-morpholino-6,7,8,9-tetrahydro-1,2,4-triazolo[5,1-*b*]-quinazoline-5(10*H*)-ones [**3b**, $\text{Q} = \text{methylthio}$, $R^1 + R^2 = (\text{CH}_2)_4$ and **3c**, $\text{Q} = \text{morpholino}$, $R^1 + R^2 = (\text{CH}_2)_4$, respectively] as main products. The UV spectra of **3b** [$\text{Q} = \text{methylthio}$, $R^1 + R^2 = (\text{CH}_2)_4$, $\lambda_{\text{max}} = 232$ and 274 nm] and **3c** [$\text{Q} = \text{morpholino}$, $R^1 + R^2 = (\text{CH}_2)_4$, $\lambda_{\text{max}} = 227$ and 270 nm] in ethanol fully supported the proposed structure **3** (see the UV rule¹ mentioned above). The ¹³C-NMR spectra of the above derivatives also nicely followed the previous conclusion¹ concerning the chemical shifts of the triazole carbon atom 2 and that of the carbonyl carbon atom {for **3b** [$\text{Q} = \text{methylthio}$, $R^1 + R^2 = (\text{CH}_2)_4$, $\delta \text{C}_2 = 163.1$ ppm and $\delta \text{C}=\text{O} = 155.4$ ppm], and for **3c** [$\text{Q} = \text{morpholino}$, $R^1 + R^2 = (\text{CH}_2)_4$, $\delta \text{C}_2 = 164.0$ ppm and $\delta \text{C}=\text{O} = 155.2$ ppm]} giving a further unequivocal proof of their structure.




The isomeric 2-methylthio- and 2-morpholino-5,6,7,8-tetrahydro-1,2,4-triazolo[1,5-a]quinazoline-9(10*H*)-ones [4b, $Q = \text{methylthio}$, $R^1 + R^2 = (CH_2)_4$ and 4c, $Q = \text{morpholino}$, $R^1 + R^2 = (CH_2)_4$, respectively] representing the novel 1,2,4-triazolo[1,5-a]quinazoline ring system formed in the above reactions in extremely low yields, were not separated but were prepared by an other synthetical route. Thus ethyl 2-oxocyclohexanecarboxylate [1, $R = C_2H_5$, $R^1 + R^2 = (CH_2)_4$] was reacted with 5-benzylamino-3-methylthio- and 5-benzylamino-3-morpholino-1*H*-1,2,4-triazole [7b ($Q = \text{methylthio}$) and 7c ($Q = \text{morpholino}$), respectively] (Scheme 2) to yield 10-benzyl-2-methylthio- and 10-benzyl-2-morpholino-5,6,7,8-tetrahydro-1,2,4-triazolo[1,5-a]quinazoline-9(10*H*)-one [8e, $Q = \text{methylthio}$, $R^1 + R^2 = (CH_2)_4$ and 8f, $Q = \text{morpholino}$, $R^1 + R^2 = (CH_2)_4$, respectively]. These benzyl derivatives were then hydrogenated to yield the expected 2-methylthio- and 2-morpholino-5,6,7,8-tetrahydro-1,2,4-triazolo[1,5-a]quinazoline-9(10*H*)-ones [4b, $Q = \text{methylthio}$, $R^1 + R^2 = (CH_2)_4$ and 4c, $Q = \text{morpholino}$, $R^1 + R^2 = (CH_2)_4$, respectively] (Scheme 2).


The UV spectra of 4b [$Q = \text{methylthio}$, $R^1 + R^2 = (CH_2)_4$, $\lambda_{\text{max}} = 206$ and 292 nm] and 4c [$Q = \text{morpholino}$, $R^1 + R^2 = (CH_2)_4$, $\lambda_{\text{max}} = 205$ and 308 nm] taken in ethanol were again in full agreement with that expected¹ for structure 4 (see the UV rule above). Also the ¹³C-NMR spectra of 4b ($\delta C_2 = 161.9$ ppm, $\delta C=O = 160.5$ ppm) and 4c ($\delta C_2 = 164.6$ ppm, $\delta C=O = 160.3$ ppm) in DMSO-*d*₆ solution corroborated unequivocally the proposed structures (see the ¹³C-NMR rule above).

The isomeric 10-benzyl-2-methylthio- and 10-benzyl-2-morpholino-6,7,8,9-tetrahydro-1,2,4-triazolo[5,1-b]quinazoline-5(10*H*)-ones [9b, $Q = \text{methylthio}$, $R^1 + R^2 = (CH_2)_4$ and 9c, $Q = \text{morpholino}$, $R^1 + R^2 = (CH_2)_4$, respectively] were prepared by the direct benzylation of the sodium salts of 3b and 3c [$R^1 + R^2 = (CH_2)_4$, $Q = \text{methylthio}$ and $Q = \text{morpholino}$, respectively] with benzyl chloride in dimethylformamide (Scheme 3).

Scheme 3



The position of the benzyl groups in **8b**, **8c**, **9b** and **9c** was unequivocally established with the help of the proton coupled ^{13}C -NMR spectra. The equivalence of the UV spectra of **3b** and **3c** with those of **9b** and **9c**, as well as of **4b** and **4c** with those of **8b** and **8c**, respectively (See Experimental) demonstrated unequivocally the dominant tautomeric structures of derivatives **3b-f** and **4b-c**, respectively, in DMSO-d_6 and in ethanol. The corresponding 2-methylthio- and 2-morpholino-6,7-dihydro-9-methoxy-benzo(h)-1,2,4-triazolo[5,1-b]quinazoline-5(12*H*)-ones (**11b** and **11c**, Q = methylthio and morpholino, respectively) (Scheme 4) representing also a novel, the benzo(h)-1,2,4-triazolo[5,1-b]quinazoline ring system were obtained from the reaction of 5-amino-3-methylthio- and 5-amino-3-morpholino-1*H*-1,2,4-triazole (**2**, Q = methylthio and morpholino, respectively) with ethyl 6-methoxy-1-oxo-1,2,3,4-tetrahydro-2-naphthoate (**10**).⁷ Unfortunately the triazolo-pyrimidinone chro-



mophore of these derivatives was overwhelmed by that of the 4-methoxyphenylacrylic acid and thus their UV spectra were not characteristic for any of the **3-6** type structures. However, their ^{13}C -NMR spectra [**11b** (Q = methylthio, $\delta \text{C}_2 = 162.0$ ppm, $\delta \text{C}=\text{O} = 154.4$ ppm) and **11c** (Q = morpholino, $\delta \text{C}_2 = 164.4$ ppm, $\delta \text{C}=\text{O} = 154.1$ ppm)] in DMSO-d_6 proved again unequivocally the proposed structure **11b** and **11c**.

EXPERIMENTAL SECTION

Melting points were determined on a Koffler-Boëtius micro apparatus and are uncorrected. The infrared spectra were obtained as potassium bromide pellets using a Perkin-Elmer 577 spectrophotometer. The ultraviolet spectra were recorded on a Varian Cary 118 and Pye Unicam SP 8-150 instruments. The ^1H -nmr and the ^{13}C -nmr measurements were performed using Varian XL-100, Bruker WM-250 and Bruker WP-80 SY instruments.

2-METHYLTHIO-6,7,8,9-TETRAHYDRO-1,2,4-TRIAZOLO[5,1-b]QUINAZOLINE-5(10H)-ONE

(3b). - A mixture of 1.3 g (0.01 mole) of 5-amino-3-methylthio-1H-1,2,4-triazole (2, Q = methylthio)⁸ 1.70 g (0.01 mole) of ethyl 2-oxocyclohexanecarboxylate [1, R = C₂H₅, R¹ + R² = (CH₂)₄] and 4 ml of glacial acetic acid was refluxed for 2 hrs. During the reaction the starting materials had dissolved and the still hot solution began to crystallise. After cooling the precipitated crystals were collected, washed with water and recrystallized from dimethylformamide to yield 1.96 g (83 %) of the title *product*, mp. 308-310°. IR: 1690 cm⁻¹ (C=O); ^1H -NMR (DMSO-d₆): δ 1.71 (m, 4H, CH₂^{7,8}), 2.38 (t, 2H, CH₂⁹), 2.52 (t, 2H, CH₂⁶), 2.59 (s, 3H, SCH₃), 12.8 (bs, 1H, NH). ^{13}C -NMR (DMSO-d₆): δ 13.4 (SCH₃), 20.9 (CH₂^{7,8}), 21.2 (CH₂⁶), 26.3 (CH₂⁹), 106.0 (C^{5a}), 146.7 (C^{9a}), 150.3 (C^{10a}), 155.4 [C⁵ (keto)], 163.1 (C₂); UV(EtOH): λ max (nm, $\epsilon \cdot 10^{-3}$): 232 (28.2), 274 (11.4); UV(10 % EtOH+90 % hydrochloric acid): λ max (nm, $\epsilon \cdot 10^{-3}$): 232 (27.4), 271 (12.7); UV(10 % EtOH+90 % sodium hydroxide): λ max (nm, $\epsilon \cdot 10^{-3}$): 234 (30.0), 289 (11.4).

Anal. Calcd. for C₁₀H₁₂N₄OS: C, 50.83; H, 5.12; N, 23.71; S, 13.57

Found: C, 51.02; H, 5.23; N, 23.77; S, 13.45

2-MORPHOLINO-6,7,8,9-TETRAHYDRO-1,2,4-TRIAZOLO[5,1-b]QUINAZOLINE-5(10H)-ONE

(3c). - A mixture of 1.69 g (0.01 mole) of 5-amino-3-morpholino-1H-1,2,4-triazole (2, Q = morpholino)⁸ 1.70 g (0.01 mole) of ethyl 2-oxocyclohexanecarboxylate [1, R = C₂H₅, R¹ + R² = (CH₂)₄] and 4 ml of glacial acetic acid was refluxed for 2 hrs. The starting material dissolved at the beginning of the reaction and shortly after the hot mixture began to crystallize. After cooling the precipitated crystals were collected and washed thoroughly with water and isopropanol to afford 2.32 g (84 %) of the title *product*, mp. 335-337°. IR: 1665 cm⁻¹ (C=O). ^1H -NMR (DMSO-d₆): δ ~1.70 (m, 4H, CH₂^{7,8}), 2.36 (t, 2H, CH₂⁹), 2.56 (t, 2H, CH₂⁶), 3.38 (t, 4H, NCH₂), 3.69 (t, 4H, OCH₂), ~12.6 (b, 1H, NH). ^{13}C -NMR (DMSO-d₆): δ 20.5 (CH₂⁶), 20.8 (CH₂⁸), 20.9 (CH₂⁷), 25.7 (CH₂⁹), 45.5 (NCH₂), 65.1 (OCH₂), 106.0 (C^{5a}), 144.8 (C^{9a}), 149.2 (C^{10a}), 155.2 [C⁵(keto)], 164.0 (C₂). UV(EtOH): λ max (nm, $\epsilon \cdot 10^{-3}$): 227 (29.9), 270 (12.1); UV(10 % EtOH+90 % hydrochloric acid): λ max (nm, $\epsilon \cdot 10^{-3}$): 227 (29.9), 270 (12.9); UV(10 % EtOH+90 % sodium hydroxide): λ max (nm, $\epsilon \cdot 10^{-3}$): 226 (36.8), 281 (10.5).

Anal. Calcd. for C₁₃H₁₇N₅O₂: C, 56.71; H, 6.22; N, 25.44

Found: C, 56.55; H, 6.18; N, 25.36

2-METHYLTHIO-5,6,7,8-TETRAHYDRO-1,2,4-TRIAZOLO[1,5-a]QUINAZOLINE-9(10H)-ONE

(4b). - A solution of 0.33 g (0.001 mole) of 10-benzyl-2-methylthio-5,6,7,8-tetrahydro-1,2,4-triazolo[1,5-a]-quinazoline-9(10H)-one (8b) in 120 ml of methanol to which was added 1 g of Selcat F (10 % Palladium catalyst on charcoal) was hydrogenated at room temperature on 1.4 MPa for 6 hrs. The catalyst was filtered off and washed twice with 5 ml portions of hot dimethylformamide. The combined filtrates were evaporated *in vacuo* to dryness and the residue was chromatographed on a silica-gel column (eluent: a 1:2 mixture of benzene and ethyl acetate) to yield 0.04 g (17 %) of the title product which after recrystallisation from acetonitrile melted at 261-263°. IR: 1680 cm^{-1} (C=O). $^1\text{H-NMR}$ (DMSO- d_6): δ 1.72 (m, 4H, $\text{CH}_2^{6,7}$), 2.35 (t, 2H, CH_2^5), 2.57 (s, 3H, SCH_3), 2.78 (t, 2H, CH_2^8). $^{13}\text{C-NMR}$ (DMSO- d_6): δ 13.5 (SCH_3), 20.4 (CH_2^8), 20.9 (CH_2^6), 21.6 (CH_2^7), 23.6 (CH_2^5), 112.4 (C^{8a}), 144.1 (C^{4a}), 148.7 (C^{10a}), 160.5 (C=O), 161.9 (C^2); UV(EtOH): λ max (nm, $\epsilon \cdot 10^{-3}$): 206 (27.1), 292 (9.6); UV(10 % EtOH+90 % hydrochloric acid): λ max (nm, $\epsilon \cdot 10^{-3}$): 206 (28.7), 289 (9.9); UV(10 % EtOH+90 % sodium hydroxide): λ max (nm, $\epsilon \cdot 10^{-3}$): 288 (10.0).

Anal. Calcd. for $\text{C}_{10}\text{H}_{12}\text{N}_4\text{OS}$: C, 50.83; H, 5.12; N, 23.71; S, 13.57

Found: C, 50.98; H, 5.22; N, 23.61; S, 13.45

2-MORPHOLINO-5,6,7,8-TETRAHYDRO-1,2,4-TRIAZOLO[1,5-a]QUINAZOLINE-9(10H)-ONE

(4c). - A solution of 0.37 g (0.001 mole) of 10-benzyl-2-morpholino-5,6,7,8-tetrahydro-1,2,4-triazolo[1,5-a]-quinazoline-9(10H)-one (8c) in 350 ml of methanol to which was added 1 g of Selcat F (10 % Palladium catalyst on charcoal) was hydrogenated at room temperature on 0.6 MPa for 6 hrs. The catalyst was filtered off and washed twice with 10 ml portions of hot dimethylformamide. The combined methanol dimethylformamide filtrates were evaporated *in vacuo* to dryness to yield 0.25 g (91 %) of the title product which after recrystallisation from acetonitrile melted at 260-262°. IR: 1650 cm^{-1} (C=O). $^1\text{H-NMR}$ (DMSO- d_6): δ 1.70 (m, 4H, $\text{CH}_2^{6,7}$), 2.31 (t, 2H, CH_2^5), 2.73 (t, 2H, CH_2^8), 3.32 (t, 4H, NCH_2), 3.68 (t, 4H, OCH_2). $^{13}\text{C-NMR}$ (DMSO- d_6): δ 20.4 (CH_2^8), 20.9 (CH_2^6), 21.3 (CH_2^7), 23.6 (CH_2^5), 45.9 (NCH_2), 65.5 (OCH_2), 110.5 (C^{8a}), 144.0 (C^{4a}), 148.1 (C^{10a}), 160.3 (C=O), 164.6 (C^2); UV(EtOH): λ max (nm, $\epsilon \cdot 10^{-3}$): 205 (29.4), 308 (10.2); UV(10 % EtOH+90 % hydrochloric acid): λ max (nm, $\epsilon \cdot 10^{-3}$): 205 (31.0), 304 (10.9); UV(10 % EtOH+90 % sodium hydroxide): λ max (nm, $\epsilon \cdot 10^{-3}$): 294 (9.6).

Anal. Calcd. for $\text{C}_{13}\text{H}_{17}\text{N}_5\text{O}_2$: C, 56.72; H, 6.22; N, 25.44

Found: C, 56.65; H, 6.30; N, 25.36

10-BENZYL-2-METHYLTHIO-5,6,7,8-TETRAHYDRO-1,2,4-TRIAZOLO[1,5-a]QUINAZOLINE-9(10H)-ONE (8b)

- A mixture of 2.2 g (0.01 mole) of 5-benzylamino-3-methylthio-1H-1,2,4-triazole (7b, Q= methylthio)⁹ and 4 ml of ethyl 2-oxocyclohexanecarboxylate [1, R= C_2H_5 , $\text{R}^1 + \text{R}^2 = (\text{CH}_2)_2$] was refluxed for 15 min. To the still hot solution 10 ml of 2-propanol was added and it was allowed to crystallise. The crystals were collected and recrystallised from acetonitrile to yield 2.4 g (74 %) of the title product, mp. 129-130°. IR: 1665 cm^{-1} (C=O). $^1\text{H-NMR}$ (DMSO- d_6): δ 1.75 (m, 4H, $\text{CH}_2^{6,7}$), 2.39 (t, 2H, CH_2^5), 2.57 (s, 3H, SCH_3), 2.81 (t, 2H,

CH₂⁸), 5.23 (s, 2H, NCH₂), 7.2-7.4 (m, 5H, ArH). ¹³C-NMR(DMSO-d₆): δ 13.5 (SCH₃), 20.3 (CH₂⁸), 20.9 (CH₂⁶), 21.9 (CH₂⁷), 23.5 (CH₂⁵), 46.1 (NCH₂), 112.1 (C^{8a}), 143.4 (C^{4a}), 149.7 (C^{10a}), 158.8 (C=O), 161.7 (C²); UV(EtOH): λ max (nm, ε.10⁻³): 206 (27.8), 287 (9.9); UV(10 % EtOH+90 % hydrochloric acid): λ max (nm, ε.10⁻³): 206 (30.4), 284 (10.6); UV(10 % EtOH+90 % sodium hydroxide): λ max (nm, ε.10⁻³): 284 (10.8).

Anal. Calcd. for C₁₇H₁₈N₄O₅: C, 62.55; H, 5.56; N, 17.17; S, 9.82

Found: C, 62.63; H, 5.68; N, 17.03; S, 9.76

10-BENZYL-2-MORPHOLINO-5,6,7,8-TETRAHYDRO-1,2,4-TRIAZOLO[1,5-a]QUINAZOLINE-

9(10H)-ONE (8c). - A mixture of 1.30 g (0.005 mole) of 5-benzylamino-3-morpholino-1H-1,2,4-triazole (7c, Q= morpholino)¹ and 3 ml of ethyl 2-oxocyclohexanecarboxylate [1, R= C₂H₅, R¹ + R²= (CH₂)₄] was refluxed 10 min. The solution obtained was evaporated *in vacuo* to dryness and the crystals obtained were recrystallised from acetonitrile to yield 1.2 g (66 %) of the title product, mp. 162-164°. IR: 1664 cm⁻¹(C=O). ¹H-NMR (DMSO-d₆): δ 1.70 (m, 4H, CH₂^{6,7}), 2.35 (t, 2H, CH₂⁵), 2.75 (t, 2H, CH₂⁸), 3.40 (t, 4H, NCH₂), 3.68 (t, 4H, OCH₂), 5.21 (s, 2H, NCH₂), 7.2-7.4 (m, 5H, ArH). ¹³C-NMR (DMSO-d₆): δ 20.3 (CH₂⁸), 20.9 (CH₂⁶), 21.7 (CH₂⁷), 23.5 (CH₂⁵), 45.8 (NCH₂), 66.0 (OCH₂), 110.0 (C^{8a}), 143.6 (C^{4a}), 148.8 (C^{10a}), 158.8 (C=O), 164.0 (C²); UV(EtOH): λ max (nm, ε.10⁻³): 206 (33.6), 310 (9.9); UV(10 % EtOH+90 % hydrochloric acid): λ max (nm, ε.10⁻³): 206 (38.1), 306 (11.2); UV(10 % EtOH+90 % sodium hydroxide): λ max (nm, ε.10⁻³): 306 (11.1).

Anal. Calcd. for C₂₀H₂₃N₅O₂: C, 65.73; H, 6.34; N, 19.17

Found: C, 65.58; H, 6.21; N, 19.11

10-BENZYL-2-METHYLTHIO-6,7,8,9-TETRAHYDRO-1,2,4-TRIAZOLO[5,1-b]QUINAZOLINE-

5(10H)-ONE (9b). - To a solution of 5.16 g (0.02 mole) of 2-methylthio-6,7,8,9-tetrahydro-1,2,4-triazolo[5,1-b]quinazoline-5(10H)-one sodium salt (3b-Na salt) (prepared by dissolving 3b in hot 1N sodium hydroxide solution, allowing it to cool and collecting the sodium salt precipitated and drying the product) in 50 ml of dimethylformamide 2.88 ml (3.16 g, 0.025 mole) of benzyl chloride was added at room temperature and it was allowed to stand for 3 days. To the solution thus obtained 50 ml of water was added dropwise with stirring. The precipitated crystals were collected and washed with water to afford 2.55 g (39 %) of the title product, mp. 220-222° (acetonitrile). IR: 1680 cm⁻¹(C=O); ¹H-NMR (DMSO-d₆): δ 1.65 (m, 4H, CH₂^{7,8}), 2.45 (t, 2H, CH₂⁹), 2.59 (s, 3H, SCH₃), 2.63 (t, 2H, CH₂⁶), 5.48 (s, 2H, NCH₂), 7.2-7.4 (m, 5H, ArH). ¹³C-NMR (DMSO-d₆): δ 13.3 (SCH₃), 20.5 (CH₂⁸), 21.1 (CH₂⁷), 21.9 (CH₂⁶), 25.0 (CH₂⁹), 108.7 (C^{5a}), 147.6 (C^{9a}), 152.2 (C^{10a}), 154.5 (C=O), 163.0 (C²); UV(EtOH): λ max (nm, ε.10⁻³): 238 (21.8), 280 (10.3); UV(10 % EtOH+90 % hydrochloric acid): λ max (nm, ε.10⁻³): 237 (20.8), 280 (11.5); UV(10 % EtOH+90 % sodium hydroxide): λ max (nm, ε.10⁻³): 238 (20.5), 280 (11.3).

Anal. Calcd. for C₁₇H₁₈N₄O₅: C, 62.55; H, 5.56; N, 17.17; S, 9.82

Found: C, 62.45; H, 5.62; N, 17.22; S, 9.73

10-BENZYL-2-MORPHOLINO-6,7,8,9-TETRAHYDRO-1,2,4-TRIAZOLO[5,1-b]QUINAZOLINE-

5(10H)-ONE (9c). - To a solution of 5.95 g (0.02 mole) of 2-morpholino-6,7,8,9-tetrahydro-1,2,4-triazolo[5,1-b]quinazoline-5(10H)-one sodium salt (**3c-Na salt**) (prepared by dissolving **3c** in hot 1*N* sodium hydroxide solution, allowing it to cool and collecting the sodium salt precipitated and drying the product) in 50 ml of dimethylformamide 2.88 ml (3.16 g, 0.025 mole) of benzyl chloride was added at room temperature and it was allowed to stand for 3 days. To the solution thus obtained 50 ml of water was added dropwise with stirring. The precipitated crystals were collected and washed with water to give 4.15 g (57 %) of the title product, mp. 213-215° (acetonitrile). IR: 1670 cm⁻¹ (C=O). ¹H-NMR(DMSO-d₆): δ 1.63 (m, 4H, CH₂^{7,8}), 2.42 (t, 2H, CH₂⁹), 2.57 (t, 2H, CH₂⁶), 3.38 (t, 4H, NCH₂), 3.67 (t, 4H, OCH₂), 5.44 (s, 2H, NCH₂), 7.25-7.4 (m, 5H, ArH). ¹³C-NMR(DMSO-d₆): δ 20.5 (CH₂⁸), 21.1 (CH₂⁷), 21.9 (CH₂⁶), 24.9 (CH₂⁹), 45.7 (NCH₂), 48.9 (NCH₂), 65.4 (OCH₂), 108.5 (C^{5a}), 146.1 (C^{9a}), 151.3 (C^{10a}), 154.7 (C=O), 163.8 (C²); UV(EtOH): λ max (nm, ε.10⁻³): 236 (29.0), 280 (13.0); UV(10 % EtOH+90 % hydrochloric acid): λ max (nm, ε.10⁻³): 236 (30.1), 280 (14.2); UV(10 % EtOH+90 % sodium hydroxide): λ max (nm, ε.10⁻³): 236 (30.1), 280 (14.3).

Anal. Calcd. for C₂₀H₂₃N₅O₂: C, 65.73; H, 6.34; N, 19.17

Found: C, 65.80; H, 6.45; N, 19.05

2-METHYLTHIO-6,7-DIHYDRO-9-METHOXY-BENZO(h)-1,2,4-TRIAZOLO[5,1-b]QUINAZOL-

INE-5(12H)-ONE (11b). - The solution of 1.3 g (0.01 mole) of 5-amino-3-methylthio-1*H*-1,2,4-triazole (**2**, Q= methylthio)⁸ and 2.48 g (0.01 mole) of ethyl 6-methoxy-1-oxo-1,2,3,4-tetrahydro-2-naphthoate (**10**)⁷ in 3 ml of dimethylformamide and 1 ml of glacial acetic acid was refluxed for 10 hrs. After cooling 30 ml of water was added to the reaction mixture, the precipitated crystals were collected and recrystallized from dimethylformamide to yield 2.55 g (81 %) of the title product, mp. 305-308°. IR: 1660 cm⁻¹ (C=O); ¹H-NMR (DMSO-d₆): δ 2.64 (s, 3H, SCH₃), 2.54 (t, 2H, CH₂⁷), 2.77 (t, 2H, CH₂⁶), 3.85 (s, 3H, OCH₃), 7.02 + 7.98 (d+d, 3H, ArH); ¹³C-NMR (DMSO-d₆): δ 13.1 (SCH₃), 15.7 (OCH₃), 19.2 (C⁷), 27.3 (C⁶), 104.3 (C^{5a}), 142.2 (C^{11b}), 150.9 (C^{12a}), 154.4 [C⁵(keto)], 162.0 (C²); UV(EtOH): λ max (nm, ε.10⁻³): 260 (25.8), 303 (18.2), 323sh (13.9); UV(10 % EtOH+90 % hydrochloric acid): λ max (nm, ε.10⁻³): 233 (18.5), 249sh (13.7), 296sh (13.7), 329 (20.2); UV(10 % EtOH+90 % sodium hydroxide): λ max (nm, ε.10⁻³): 258 (29.4), 302 (19.1), 323sh (14.1), 337sh (9.2).

Anal. Calcd. for C₁₅H₁₄N₄O₂S: C, 57.31; H, 4.49; N, 17.82; S, 10.20

Found: C, 57.54; H, 4.56; N, 17.53; S, 9.93

2-MORPHOLINO-6,7-DIHYDRO-9-METHOXY-BENZO(h)-1,2,4-TRIAZOLO[5,1-b]QUINAZOL-

INE-5(12H)-ONE (11c). - The solution of 1.69 g (0.01 mole) of 5-amino-3-morpholino-1*H*-1,2,4-triazole (**2**, Q= morpholino)⁸ and 2.48 g (0.01 mole) of ethyl 6-methoxy-1-oxo-1,2,3,4-tetrahydro-2-naphthoate (**10**)⁷ in 3 ml of dimethylformamide and 1 ml of glacial acetic acid was refluxed for 10 hrs. After cooling 30 ml of water was add-

ed to the reaction mixture, the precipitated crystals were collected and recrystallized from dimethylformamide to yield 2.36 g (67 %) of the title product, mp. 302-305°. IR: 1665 cm⁻¹ (C=O); ¹H-NMR (TFA: δ 3.0 (m, 4H, CH₂CH₂), 3.80 (t, 4H, NCH₂), 4.02 (s, 3H, OCH₃), 4.1 (t, 4H, OCH₂), 7.05 + 7.85 (dd, 3H, ArH); ¹³C-NMR (DMSO-d₆: δ 15.7 (OCH₃), 19.2 (C⁷), 27.4 (C⁶), 45.8 (NCH₂), 65.4 (OCH₂), 104.5 (C^{5a}), 142.0 (C^{11b}), 150.0 (C^{12a}), 154.1 [C⁵(keto)], 164.4 (C²); UV(EtOH): λ max (nm, ε.10⁻³): 228sh (16.4), 232sh (15.8), 312 (18.7); UV(10 % EtOH+90 % hydrochloric acid): λ max (nm, ε.10⁻³): 228sh (16.7), 320 (18.7); UV(10 % EtOH+90 % sodium hydroxide): λ max (nm, ε.10⁻³): 248 (18.1), 304 (17.8).

Anal. Calcd. for C₁₈H₁₉N₅O₃: C, 61.18; H, 5.42; N, 19.82

Found: C, 61.07; H, 5.33; N, 19.85

ACKNOWLEDGEMENT. -The authors wish to express their thanks to Miss Ilona Sztruhár for recording the UV spectra, to Mrs Zsoltné Bíró for recording the IR spectra to Mr István Parragi for recording the NMR spectra and to Mrs Jánosné Ifjú and Mrs Lászlóné Nyikos for technical assistance.

REFERENCES

- † Part XV. of the On Triazole Series. For Part XIV, see A. M. Orendt, J. Michl and J. Reiter, *Magn. Res. Chem.*, **27**, 1 (1989)
1. J. Reiter, L. Pongó and P. Dvortsák, *Tetrahedron*, **43**, 2497 (1987)
2. K. Esses-Reiter and J. Reiter, *J. Heterocyclic Chem.*, **24**, 1503 (1987)
3. N. Heimbach, U.S. Pat. No. 2 444 607; *Chem. Abstr.*, **42**, 7178f (1948)
4. J. W. Cook, R. P. Gentles, and S. H. Tucker, *Rec. Trav. Chim. Pays-Bas*, **69**, 343 (1950)
5. K. Sirakawa, *Yakugaku Zasshi*, **79**, 1487 (1959); *Chem. Abstr.*, **54**, 11039h (1960)
6. B. Stanovnik and M. Tisler, *Croat. Chem. Acta.*, **44**, 415 (1972); *Chem. Abstr.*, **78**, 43405p (1973)
7. H. Immer and J. F. Bagli, *J. Org. Chem.*, **33**, 2457 (1968)
8. J. Reiter, T. Somorai, Gy. Jerkovich and P. Dvortsák, *J. Heterocyclic Chem.*, **19**, 1157 (1982)
9. J. Reiter, T. Somorai, P. Dvortsák and Gy. Bujtás, *ibid.*, **22**, 385 (1985)

(Received November 30, 1987; in revised form January 23, 1989)